Philip Morris Stock Gains as FDA Grants Modified-Risk Status to Zyn Products

In a move reflecting the strategic pivot toward alternative products, UBS raised its price target for Philip Morris International (PM) to $182.00 from $168.00. This optimism follows the U.S. FDA's authorization for the company to market 20 Zyn products as 'modified-risk' alternatives, highlighting reduced health risks compared to traditional cigarettes. Smoke-free products now account for more than 43% of the company's total net revenues, marking a significant milestone in its business transformation.

This regulatory approval strengthens Zyn's position against competitors such as British American Tobacco’s Velo brand, which is also vying for dominance in the nicotine pouch segment. Per market data, this shift occurs as major tobacco firms face declining traditional cigarette volumes, making the FDA's decision a critical competitive advantage for Philip Morris in the U.S. market. Analysts suggest that the modified-risk claim will streamline marketing efforts toward adult smokers seeking reduced-harm options.

At the close on July 1, 2026, PM stock stood at $177.69, having reached a session high of $181.54. Traders are now watching for consolidation near these levels as the stock approaches the new UBS target. Looking ahead, investors should monitor the Michigan Consumer Sentiment index scheduled for June 26, 2026, which may provide broader context on consumer spending trends within the staples sector.